Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104388 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
A Phase 2 study of Corneal Epithelial Disorders, sponsored by Senju Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 17
- Study locations
NCT02104388 is a Phase 2 study of Corneal Epithelial Disorders that has completed, run by Senju Pharmaceutical Co.. The registered enrollment target is 69 participants. The trial reports 17 study locations across 10 states.
The verdict
NCT02104388, a Phase 2 study of Corneal Epithelial Disorders, has completed, sponsored by Senju Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
Conditions Studied
Interventions
- DRUG SJP-0035 Ophthalmic Solution
- DRUG Vehicle of SJP-0035 Ophthalmic Solution
Study Locations (17)
California
- Senju Investigational Site - Glendale
- Senju Investigational Site - Glendora
- Senju Investigational Site - Huntington Beach
- Senju Investigational Site - Lancaster
- Senju Investigational Site - Newport Beach
- Senju Investigational Site - Pasadena
- Senju Investigational Site - Petaluma
- Senju Investigational Site - Santa Maria
Arkansas
- Senju Investigational Site - Little Rock
Illinois
- Senju Investigational Site - Hoffman Estates
Kentucky
- Senju Investigational site - Edgewood
Missouri
- Senju Investigational Site - Kansas City
New Jersey
- Senju Investigational Site - Palisades Park
New York
- Senju Investiational Site - Rochester
North Carolina
- Senju Investigational Site - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-04-08 |
| Est. Completion | 2015-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02104388
The ClinicalTrials.gov registry entry for NCT02104388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senju Pharmaceutical Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Corneal Epithelial Disorders appearing as the primary indexed condition, and to 2 interventions - of which SJP-0035 Ophthalmic Solution is the first listed.
NCT02104388 reports 17 study locations spanning 10 distinct geographic areas - top geographies include California, Arkansas, Illinois.
Frequently Asked Questions
What is clinical trial NCT02104388 about?
NCT02104388 is a clinical study titled "Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders". The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
What is the current status of trial NCT02104388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2014-04-08. Estimated completion is 2015-08-04.
What conditions does trial NCT02104388 study?
This clinical trial studies the following conditions: Corneal Epithelial Disorders.
What interventions are being tested in trial NCT02104388?
The interventions under investigation include: SJP-0035 Ophthalmic Solution (DRUG), Vehicle of SJP-0035 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02104388?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02104388 being conducted?
This trial has 17 study locations across Arkansas, California, Illinois, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Epithelial Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.